Attachment II - ftge 2 
9105-008 
9105-009* 
9110-010* 
9110-011 
9110-012* 
9202-013* 
9202-014 
9202-015 
9202-016* 
9202-017 6 
(M) Ledley, Fred D.; Woo, Savio; Ferry, George; and Hartwell, Whigennand; Baylor College of Medicine, 
Houston, Texas; Hepatocellular Transplantation in Acute Hepatic Failure and Targeting Genetic Markers to 
Hepatic Cells. 
RAC Approval: 5-30-91/NIH Approval: 7-12-91 
CLOSED: Protocol Never Initiated 
(M) Lotze, Michael T.; University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; The 
Administration of Interleukin-2 and Tumor Infiltrating Lymphocytes to Patients with Melanoma. 
RAC Approval: 5-30-91/NIH Approval: 1-17-92 
Minor Modification: 11-30-92 
(T) Rosenberg, Steven A.; National Institutes of Health, Bethesda, Maryland; Immunization of Cancer Patients 
Using Autologous Cancer Cells Modified by Insertion of the Gene for Tumor Necrosis Factor (TNF). 
RAC Approval: 10-7-91/NIH Approval: 10-15-91 
Minor Modification: 7-9-92 
(T) Rosenberg, Steven A.; National Institutes of Health, Bethesda, Maryland; Immunization of Cancer Patients 
Using Autologous Cancer Cells Modified by Insertion of the Gene for Interleukin-2 (IL-2). 
RAC Approval: 10-7-91/NIH Approval: 10-15-91 
(T) Wilson, James M.; University of Pennsylvania Medical Cenyrt, Philadelphia, Pennsylvania; Ex Vivo Gene 
Therapy of Familial Hypercholesterolemia. 
RAC Approval: 10-8-91/NIH Approval: 11-14-91 
Minor Modification: 12-3-92 
Minor Modification: 8-18-93 
(T) Nabel, Gary J.; University of Michigan, Ann Arbor, Michigan; Immunotherapy of Malignancy by In Vivo 
Gene Transfer into Tumors. 
RAC Approval: 2-10-92/NIH Approval: 4-17-92 
Minor Modification: 1-22-93 
Minor Modification: 1-93 
CLOSED: 11-19-92 
(M) Cornetta, Kenneth; Indiana University, Indianapolis, Indiana; Retroxiral-Mediated Gene Transfer of Bone 
Marrow Cells during Autologous Bone Marrow Transplantation for Acute Leukemia. 
RAC Approval: 2-11-92/NIH Approval: 4-17-92 
(M) Economou, James S. and Belldegrun, Arie; University of California at Los Angeles, Los Angeles, 
California; The Treatment of Patients with Metastatic Melanoma and Renal Cell Cancer Using In Vitro 
Expanded and Genetically-Engineered (Neomycin Phosphotransferase) Bulk, CD8 ( + ) and/or CD4( + ) 
Tumor Infiltrating Lymphocytes and Bulk, CD8( + ) and/or CD4( + ) Peripheral Blood Leukocytes in 
Combination with Recombinant Interleukin-2 Alone, or with Recombinant Interleukin-2 and Recombinant 
Alpha Interferon. 
RAC Approval: 2-11-92/NTH Approval: 4-17-92 
(T) Freeman, Scott M.; Tulane University Medical Center, New Orleans, Louisiana; Gene Transfer for the 
Treatment of Cancer. 
RAC Approval: 2-10-92/NIH Approval: 2-5-93 
Minor Modification: 8-6-93 
(M) Greenberg, Philip D. and Riddell, Stanley, Fred Hutchinson Cancer Research Center, University of 
Washington, Seattle; Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy using 
Genetically Modified CD8 + HIV-Specific T Cells in HIV Seropositive Individuals. 
RAC Approval: 2-11-92/NIH Approval: 4-17-92 
Major Amendraent/RAC Approval: 9-9-93 
Major Amendment/NIH Approval: 10-7-93 
Recombinant DNA Research, Volume 20 
[93] 
